Leerink Partners Keeps a Hold Rating on Incyte (INCY)
Leerink Partners analyst Andrew Berens maintained a Hold rating on Incyte (INCY) today and set a price target of $87.00. The company’s shares closed last Tuesday at $99.95.
According to TipRanks.com, Berens is a 5-star analyst with an average return of 12.3% and a 65.5% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Zentalis Pharmaceuticals.
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $105.46, which is a 4.4% upside from current levels. In a report issued on July 20, Credit Suisse also maintained a Hold rating on the stock with a $100.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $110.37 and a one-year low of $62.48. Currently, Incyte has an average volume of 1.45M.
Based on the recent corporate insider activity of 146 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY: